The NULISA™ Platform sets a new standard in proteomic analysis with attomolar sensitivity, allowing for unprecedented biomarker detection and quantitation.
By leveraging a proprietary sequential immunocomplex capture and release mechanism and the latest advances in Next Generation Sequencing (NGS), the NULISA technology provides both ultra-high sensitivity and scalable multiplexing.
ULTRA HIGH SENSITIVTY
Ultra-high attomolar sensitivity and lower limits of detection for the discovery and detection of critical biomarkers.
BROAD DYNAMIC RANGE
With single plex up to 7 logs and multiplex up to 12 logs of dynamic range, NULISA enables quantitation across a broad range of biological expression levels without the need for dilution.
FLEXIBLE PLEX
Flexible, scalable chemistry provides the ability to focus in on a single target, or multiplex hundreds to potentially thousands of targets in a single sample on one platform.
NULISA assays maintain performance from single qPCR to multiplex NGS analyses.
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
Looking for more information? Contact us today and a representative will reach out to you soon.
Alamar Biosciences, Inc.
47071 Bayside Pkwy
Fremont, CA 94538
1 (510) 626-9888
Fax: (510) 605-5062